MY200934A - Methods Of Treating Bacterial Infections - Google Patents

Methods Of Treating Bacterial Infections

Info

Publication number
MY200934A
MY200934A MYPI2020001141A MYPI2020001141A MY200934A MY 200934 A MY200934 A MY 200934A MY PI2020001141 A MYPI2020001141 A MY PI2020001141A MY PI2020001141 A MYPI2020001141 A MY PI2020001141A MY 200934 A MY200934 A MY 200934A
Authority
MY
Malaysia
Prior art keywords
subject
methods
subjects
treating bacterial
transplant
Prior art date
Application number
MYPI2020001141A
Other languages
English (en)
Inventor
Elizabeth Alexander
Jeff Loutit
Michael N Dudley
Original Assignee
Melinta Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY200934(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Llc filed Critical Melinta Therapeutics Llc
Publication of MY200934A publication Critical patent/MY200934A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2020001141A 2017-10-03 2018-10-01 Methods Of Treating Bacterial Infections MY200934A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MY200934A true MY200934A (en) 2024-01-24

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001141A MY200934A (en) 2017-10-03 2018-10-01 Methods Of Treating Bacterial Infections

Country Status (16)

Country Link
US (2) US11376237B2 (ar)
EP (1) EP3691652A4 (ar)
JP (1) JP2020536092A (ar)
KR (1) KR20200066664A (ar)
CN (1) CN111432821A (ar)
AU (1) AU2018345317B2 (ar)
BR (1) BR112020006658A2 (ar)
CA (1) CA3078238A1 (ar)
CL (1) CL2020000892A1 (ar)
JO (1) JOP20200075A1 (ar)
MX (1) MX2020003670A (ar)
MY (1) MY200934A (ar)
PH (1) PH12020550249A1 (ar)
SG (1) SG11202003009QA (ar)
TW (2) TW201922241A (ar)
WO (1) WO2019070591A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200075A1 (ar) 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية
US20240207292A1 (en) * 2021-03-24 2024-06-27 Trustees Of Tufts College Boronic acid compounds, compositions and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
MX363678B (es) 2013-05-28 2019-03-29 Morphochem Aktiengesellschaft Fuer Komb Torische Chemie Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
JP6945452B2 (ja) * 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
PL3319609T3 (pl) 2015-07-09 2022-12-05 Washington University Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
KR102768209B1 (ko) 2017-01-09 2025-02-18 멜린타 테라퓨틱스, 엘엘씨 세균 감염을 치료하는 방법
JOP20200075A1 (ar) * 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية

Also Published As

Publication number Publication date
CA3078238A1 (en) 2019-04-11
TW201922241A (zh) 2019-06-16
EP3691652A4 (en) 2021-07-07
AU2018345317B2 (en) 2024-10-24
MX2020003670A (es) 2020-08-03
BR112020006658A2 (pt) 2020-09-24
AU2018345317A1 (en) 2020-05-07
SG11202003009QA (en) 2020-04-29
JP2020536092A (ja) 2020-12-10
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
KR20200066664A (ko) 2020-06-10
WO2019070591A1 (en) 2019-04-11
TW202400146A (zh) 2024-01-01
US11376237B2 (en) 2022-07-05
US20220288024A1 (en) 2022-09-15
US12533342B2 (en) 2026-01-27
PH12020550249A1 (en) 2021-02-15
CN111432821A (zh) 2020-07-17
EP3691652A1 (en) 2020-08-12
CL2020000892A1 (es) 2020-10-23

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MY205856A (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
TN2019000040A1 (en) Anti-tim-3 antibodies
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12020500225A1 (en) Anti- cd137 antibodies
MY199019A (en) Pd-1 antibodies
MX2017014020A (es) Terapia antimicrobiana.
PH12016501680A1 (en) Anti-egfrviii antibodies and uses thereof
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2022004766A (es) Terapias combinadas con venetoclax e inhibidores de tim-3.
PH12020550249A1 (en) Methods of treating bacterial infections
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
MX2022007775A (es) Composición para usarse en terapia de microbiota.
EP4378535A3 (en) Antibiotic formulations for lower back pain
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
PH12021550035A1 (en) Combination therapy
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
WO2019032810A3 (en) Methods and materials for identifying and treating bet inhibitor-resistant cancers